ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2909

Tolerogenic Splenic IDO+ Dendritic Cells from the Mice Treated with Induced-Treg Cells Could Suppress Collagen-Induced Arthritis

Jie Yang1, Huahua Fan2 and Hejian Zou1, 1Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040, China, Shanghai, China, 2Blood Engineering Laboratory, Shanghai Blood Center, Shanghai 200051, China, Shanghai, China

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: T-Regulatory Cells and dendritic cells

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Animal Models II

Session Type: Abstract Submissions (ACR)

Background/Purpose

As well known, Foxp3+ regulatory T cells play a crucial role in maintaining immune tolerance. It was reported that TGF-β-induced Tregs (iTregs) could retain Foxp3 expression and immune suppressive activity in the collagen-induced arthritis (CIA). However, the mechanisms whereby transferred iTregs suppressed immune response, especially the interplay between iTregs and DCs in vivo, remained incompletely understood. In this study, whether splenic DCs were involved in iTreg-based suppression and how these DCs further inhibited CIA were determined.

Methods

In vitro, iTregs were induced by TGF-β and adoptive transferred into established CIA mice. After 7 days, splenic CD11c+DCs were isolated, termed ‘DCiTreg’. The phenotype, the expression of cytokines and function-associated molecules, the immunogenicity and the suppression on CD4/CD8 T cell differentiation of DCiTreg were assessed. To determine the suppression in vivo, 5×105 of DCiTreg were re-infused into the new CIA mice. Clinical and histopathologic scores, cytokine and anti-CII antibody secretion in serum were analyzed. And it also was determined the expression of Foxp3 and function of Tregs after IDO+DCs transferred. Additionally, the role of IDO in the inhibitory effect of DCiTreg was determined by 1-MT blocking in vitroand in CIA mice.

Results After iTregs adoptive transferred, isolated DCiTreg exhibited a series of tolerogenic characteristics. Compared with splenic DCs isolated from CIA mice (DCCIA), DCiTreg expressed obviously lower levels of MHC molecule (IA-IE) and co-stimulatory molecules (CD80, CD86 and CD40). And IL-12p40 and IL-6 production by DCiTreg were negligible, while high levels of IL-10 and TGF-β were expressed; especially enhanced level of IDO by DCiTreg was detected, and CD11b+DCs were found as a major contributor of IDO expression in iTreg-treated CIA mice. In the proliferation assay, DCiTreg showed the poor ability to expand effector T cells and had the effective inhibitory potency. Meanwhile, after CD11b+IDO+DCiTreg re-infused, a remarkable anti-arthritic activity, improved clinical scores and histological end-points were found. Also, serological levels of TNF-α, IL-6, IL-17 and anti-CII antibodies showed significantly low and TGF-β production was high in the DCiTreg-treated group. Conversely, DCCIA could not suppress CIA completely. And IDO+DCs could induce the generation and proliferation of functional Foxp3+Tregs in vitro and in CIA mice. Moreover, DCiTreglost the inhibitory ability on CIA when they pretreated 1-MT.

Conclusion

These findings suggested that iTregs could inhibit CIA via tolerogenic splenic DCs formation. These tolerogenic splenic DCs could further effectively dampen the severity and progression of CIA in the IDO-dependent manner, which was associated with modulation of inflammatory cytokine and anti-CII antibody secretion and induction of new iTregs. Thus, the potential therapeutic effect of iTreg in CIA and RA is likely to be maintained, even enlarged by their effects on DCs in vivo.


Disclosure:

J. Yang,
None;

H. Fan,
None;

H. Zou,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tolerogenic-splenic-ido-dendritic-cells-from-the-mice-treated-with-induced-treg-cells-could-suppress-collagen-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology